The expansion includes a new R&D laboratory and the installation of a 12,000-liter reactor at one of the company’s manufacturing facilities on its Paullo site in Milan, Italy.
Cambrex, a small-molecule company providing drug substance, drug product, and analytical services across the drug lifecycle, announced on March 14, 2019 that it has completed the expansion of a new 150-m2 R&D laboratory at its site in Paullo, Milan, Italy.
The R&D laboratory includes both chemistry and analytical development capabilities, with the installation of semi-automated glass-lined reactors as well as analytical instruments, including multiple high- and ultra-performance liquid chromatography, as well as gas chromatography systems, which have now been qualified and validated, the company reports. To complement investments at other Cambrex sites, the new laboratory has also installed a flow chemistry system to allow for continuous manufacturing development.
Additionally, the company has installed a new 12,000-liter reactor into one of its cGMP manufacturing facilities at the site. The installation of the reactor, along with the replacement of centrifuges with new equipment in one of the site’s seven production departments, is part of a $3-million investment to upgrade and improve the efficiency of the plant, which manufactures intermediates and generic APIs under GMP conditions.
“This investment is part of our ongoing strategy to ensure that the site can adapt to the growing and evolving needs of the generic API industry,” said Aldo Magnini, managing director, Cambrex Milan, in a company press release. “Investing in key technologies such as continuous flow will allow us to look at new opportunities for the site to expand our portfolio of generic products, in a similar manner to the investment in highly potent API containment that we undertook in 2017, which allowed us to increase the number of new highly-potent oncology products in development.”
Source: Cambrex
Benuvia Granted GMP Certification by Brazil National Health Surveillance Agency
March 14th 2025The certification allows Benuvia to produce pharmaceutical products for companies, either local to Brazil or international, that may be looking for compliant and high-quality production capabilities in the Brazilian pharmaceutical market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.